Loading clinical trials...
Loading clinical trials...
An Open-label, Phase II Study of Durvalumab (MEDI4736) in Combination With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Conditions
Interventions
Durvalumab
Cetuximab
Locations
1
United States
UC Health
Cincinnati, Ohio, United States
Start Date
October 23, 2018
Primary Completion Date
December 1, 2024
Completion Date
December 1, 2024
Last Updated
December 8, 2023
NCT04585750
NCT07457346
NCT06636188
NCT07065630
NCT05526924
NCT07447050
Lead Sponsor
Trisha Wise-Draper
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions